Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48 Plus Gemcitabine vs RC48 Plus Toripalimab in MIBC (GUARD-02)
NCT07693959Phase 3Recruiting
- Sponsor
- Zhiquan Hu
- Start
- Jul 2026
- Primary completion
- Jul 2028
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in muscle-invasive bladder cancer (MIBC) comparing Experimental Arm (RC48 + Gemcitabine) with Active Comparator Arm (RC48 + Toripalimab) (2 arms). Primary endpoint: Pathological Complete Response. Started Jul 2026; status: recruiting.
02
Drugs
disitamab vedotingemcitabine
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT07693959.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07693959.